Gapping up
In reaction to strong earnings/guidance:
- GERN +32.3%, CMCM +11.1%, CSIQ +2.6%, VUZI +1.3%, DAN +1.3%, (guidance)
M&A news:
- CSRA +2.3% (receives unsolicited proposal from CACI International (CACI) for $44.00/share in cash & stock, says Board will carefully review and consider the rival bid), .
Other news:
- CDTX +22.8% (reports 'positive' topline results from the global, randomized Phase 2 STRIVE clinical trial of its lead antifungal candidate rezafungin acetate)
- CLRB +18.8% (granted orphan drug designation by the FDA for its treatment of neuroblastoma)
- MTNB +9.2% (appoints Jerome D. Jabbour as CEO effective immediately; provides corporate update)
- BCS +4.8% (Edward Bramson activist fund takes 5.16% stake in BCS)
- JKS +4.7% (in sympathy with CSIQ earnings)
- NWL +3.3% (Carl Icahn discloses 6.86% active stake)
- NS +1% (announces that yesterday's decision by the FERC to revise its 2005 Policy Statement for Recovery of Income Tax costs is not expected to have a material impact on the earnings or cash flow)
Analyst comments:
- NCMI +1.6% (upgraded to Buy at B. Riley FBR)